FY2027 Earnings Forecast for JNJ Issued By Erste Group Bank

Key Points

• Erste Group Bank cut its FY2027 EPS forecast for Johnson & Johnson to $12.65 from $12.83, though the estimate remains above the current consensus of $11.09.
• J&J reported third-quarter adjusted EPS of $2.59, beating estimates of $2.53, while revenue rose 5.9% year over year to $25.4 billion; management raised its FY2026 adjusted EPS guidance to $11.05–$11.15.
• The company declared a quarterly dividend of $1.34 per share, equal to $5.36 annually and a 2.2% yield, while shares were reported down 5.6% and analysts maintained a consensus “Moderate Buy” rating.

Johnson & Johnson (NYSE:JNJ - Free Report) - Stock analysts at Erste Group Bank reduced their FY2027 EPS estimates for Johnson & Johnson in a research note issued on Thursday, October 8th. Erste Group Bank analyst H. Engel now forecasts that the company will earn $12.65 per share for the year, down from their prior forecast of $12.83. The consensus estimate for Johnson & Johnson's current full-year earnings is $11.09 per share.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.40 billion for the quarter, compared to analysts' expectations of $25.38 billion. During the same quarter in the prior year, the company earned $2.80 earnings per share. The business's quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS.

Several other equities research analysts also recently weighed in on the stock. Royal Bank Of Canada upped their target price on shares of Johnson & Johnson from $287.00 to $290.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 6th. Citigroup raised their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a "buy" rating in a research report on Monday, October 5th. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Bank of America reaffirmed a "neutral" rating and set a $278.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, September 29th. Finally, TD Cowen increased their price objective on Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $276.22.

Johnson & Johnson Trading Down 5.6%

Shares of JNJ stock opened at $248.90 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The stock has a market capitalization of $599.83 billion, a P/E ratio of 28.84, a price-to-earnings-growth ratio of 2.70 and a beta of 0.21. The company has a 50 day moving average price of $265.89 and a 200 day moving average price of $249.37. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07.

Institutional Investors Weigh In On Johnson & Johnson

A number of large investors have recently modified their holdings of the company. Outlook Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $28,000. Matrix Trust Co grew its stake in Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after buying an additional 54 shares during the last quarter. Hyposwiss Advisors SA acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $42,000. Montgomery Financial Services LLC acquired a new position in Johnson & Johnson during the second quarter worth approximately $43,000. Finally, Polaris Financial Partners purchased a new stake in Johnson & Johnson in the third quarter valued at approximately $56,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 87,569 shares of company stock valued at $23,064,544. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. Johnson & Johnson's payout ratio is currently 62.11%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported adjusted third-quarter EPS of $2.59, above the $2.53 analyst consensus, while revenue rose 5.9% year over year to $25.4 billion. Innovative Medicine led growth, including strong oncology demand and a 68% increase in TREMFYA sales to approximately $2.4 billion. Johnson & Johnson reports Q3 2026 results and raises guidance
• Positive Sentiment: Management raised its 2026 outlook to adjusted EPS of $11.05–$11.15 and revenue of $101.0–$101.4 billion. The guidance midpoint is broadly in line with current analyst expectations and signals continued confidence in pharmaceutical growth. Johnson & Johnson raises 2026 guidance as quarterly sales climb
• Positive Sentiment: The board declared a quarterly dividend of $1.34 per share, or $5.36 annualized, supporting JNJ’s income-investment appeal. Johnson & Johnson announces quarterly dividend
• Neutral Sentiment: Johnson & Johnson is leaning toward spinning off its hips-and-knees orthopedics business. The move could sharpen the company’s focus and unlock value, but execution details and timing remain uncertain. J&J is leaning toward spinning out its hips-and-knees business
• Negative Sentiment: MedTech grew operationally by only about 2.5% and missed expectations, with weakness in Surgery and Cardiovascular markets outside the United States. Middle East-related budget pressure also weighed on medical-device sales, raising concerns about the segment’s near-term growth.
• Negative Sentiment: Reported net income fell sharply to $210 million, or $0.09 per share, because of special charges tied primarily to the proposed talc litigation resolution, the Firefly Bio acquisition and the Sail Biomedicines collaboration. These charges overshadowed the adjusted earnings beat. Johnson & Johnson falls after quarterly report despite higher outlook
• Negative Sentiment: Erste Group Bank lowered its FY2027 EPS estimate to $12.65 from $12.83, reflecting concerns about future costs from business-development activity and ongoing operational headwinds. Johnson & Johnson analyst estimate update

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.